Prognostic significance of baseline C-reactive protein/albumin ratio for long-term outcomes in advanced gastric cancer under immunochemotherapy

Table 3 Univariate and multivariate analyses of prognostic factors for progression-free survival

Variables	Univariate		Multivariate
	P value	HR (95%CI)	P value	HR (95%CI)
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	< 0.001	0.34 (0.24-0.50)	< 0.001	0.42 (0.28-0.62)
MMR status (pMMR vs dMMR)	< 0.001	0.25 (0.13-0.48)	0.001	0.34 (0.18-0.65)
CAR (high vs low)	0.003	0.57 (0.40-0.82)	0.034	0.67 (0.46-0.97)
Sex (male vs female)	0.908	1.02 (0.70-1.49)
Age (≥ 60 vs < 60), years	0.114	1.36 (0.93-2.00)
BMI (< 25 vs ≥ 25), kg/m2	0.813	1.06 (0.66-1.70)
CEA (< 3 vs ≥ 3), ng/mL	0.853	1.04 (0.72-1.50)
CA199 (< 37 vs ≥ 37), ng/mL	0.365	1.19 (0.82-1.73)
ECOG (0 vs 1)	0.821	1.04 (0.72-1.52)
Staging (III vs IV)	< 0.001	2.55 (1.74-3.75)	0.015	1.67 (1.10-2.52)
Differentiation (poorly/undifferentiated vs medium/high)	0.041	0.45 (0.21-0.97)	0.235	0.62 (0.29-1.36)
Site (gastric and esophageal binding vs stomach)	0.772	0.94 (0.63-1.40)
Peritoneal metastasis (no vs yes)	< 0.001	2.08 (1.44-3.00)	< 0.001	1.95 (1.31-2.88)
Liver metastasis (no vs yes)	0.072	1.47 (0.97-2.25)
EBV status (infect vs no-infect)	0.099	0.47 (0.19-1.15)
Neutrophil	0.280	1.04 (0.97-1.11)
Lymphocyte	0.971	1.01 (0.75-1.36)

HR: Hazard ratio; CI: Confidence interval; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; CAR: C-reactive protein/albumin ratio; BMI: Body mass index; CEA: Carcinoembryonic-antigen; CA199: Carbohydrate antigen 199; ECOG: Eastern Cooperative Oncology Group; EBV: Epstein-Barr virus.